News & Notes
- Our New Innovator Seminar Series: Session 2 - Design Research Aims Around Commercially-relevant Milestones Set for Thursday, Mar. 27th: ... View More
- Save the Date for the 8th Annual Celebration of Technology & Innovation, March 6th ... View More
- Apply for the next Kauffman FastTrac® TechVenture™ Deadline March 21st ... View More
- Emory Startup AKESOgen and VA Million Veteran Program Collaborate to Genotype 105,000 Veterans ... View More
- Emory Licensee Baxter Submits BLA For Approval Of OBI-1 For Patients With Acquired Hemophilia A ... View More
- Two Emory Technologies are Finalist for 2nd Annual Atlanta Magazine Groundbreaker Awards ... View More
- Emory Technology Featured by medGadget, an Online Journal of the Latest Medical Gadgets, Technologies, and Discoveries. ... View More
- Emory Start-up Velocity Choosen as One of Four Finalist for 2013 Intel Innovation Awards ... View More
- Emory start-up Neurotrack Raises Series A for its Alzheimer’s Disease Behavioral Biomarker ... View More
- Emory Technology Included in Varian's Edge Radiosurgery Suite ... View More
Recognizing Unmet Needs: Moore Makes the Most of His Lab's RSV Research
Martin Moore, PhD
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, viral pneumonia, and viral death in infants both in the U.S. and worldwide. Almost all children will have been infected with RSV by their second birthday. And yet, this killer of 200,000 infants annually was not the focus of as much laboratory research as might be expected.
"Before deciding on what to work on as a post-doc, I made a matrix of viral diseases on a sheet of paper, clinical impact versus number of RO1s (NIH independent investigator grants)," says Martin Moore, PhD, an assistant professor in Emory s in infectious diseases, and a faculty member of the Children's Center for Immunology and Vaccines (CCIV). "RSV was the virus that had the highest ratio of these two things. It was important, and not enough people were studying it."